Alzheimer’s Disease/Dementia News

People with higher levels of antioxidants in their blood may be less likely to develop dementia, researchers reported in Neurology.

Alzamend Neuro Inc. has announced the launch of a phase 2A trial for its AL001 treatment for mild to moderate Alzheimer’s dementia.

The Indian Health Service has announced it will allocate $5 million in funding toward resources to address Alzheimer’s disease among tribal communities.

The FDA announced it will review a resubmitted supplemental new drug application for Nuplazid for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis.

The FDA granted breakthrough device designation and permitted marketing for the first in vitro diagnostic test for early detection of amyloid plaques associated with Alzheimer’s disease.

The FDA has granted fast track designation for Vaxxinity Inc.’s UB-311, an anti-amyloid beta immunotherapeutic vaccine, for the treatment of Alzheimer’s disease.

The FDA and European Commission have both granted orphan drug designation to AviadoBio for its new gene therapy to treat frontotemporal dementia, according to a company press release.

Those with amnestic mild cognitive impairment who used the BrainHQ app for visual speed and attention exercises improved neuropsychological measures of speed, attention, memory and connectivity.

Together Senior Health, a digital therapeutics and cognitive health firm, has announced the launch of its cognitive health platform, which it hopes will reduce the impact of memory loss in those with Alzheimer’s disease and dementia.

Patients with Alzheimer’s disease who are treated with lecanemab have shown the potential to reaccumulate brain amyloid after removal of the drug, a speaker said at the 2022 American Academy of Neurology annual meeting.